RT Journal Article
SR Electronic
T1 Fluoroquinolone-induced serious, persistent, multisymptom adverse effects
JF BMJ Case Reports
FD BMJ Publishing Group Ltd
SP bcr2015209821
DO 10.1136/bcr-2015-209821
VO 2015
A1 Golomb, Beatrice Alexandra
A1 Koslik, Hayley Jean
A1 Redd, Alan J
YR 2015
UL http://casereports.bmj.com/content/2015/bcr-2015-209821.abstract
AB We present a case series of four previously healthy, employed adults without significant prior medical history in each of whom symptoms developed while on fluoroquinolones (FQs), with progression that continued following discontinuation evolving to a severe, disabling multisymptom profile variably involving tendinopathy, muscle weakness, peripheral neuropathy, autonomic dysfunction, sleep disorder, cognitive dysfunction and psychiatric disturbance. Physicians and patients should be alert to the potential for FQ-induced severe disabling multisymptom pathology that may persist and progress following FQ use. Known induction by FQs of delayed mitochondrial toxicity provides a compatible mechanism, with symptom profiles (and documented mechanisms of FQ toxicity) compatible with the hypothesis of an exposure-induced mitochondrial neurogastrointestinal encephalomyopathy.